SCHEMBL57542

SCHEMBL57542

O=C(O)c1cc(Cl)nc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.69
HTT P42858 2/20 0.67
USP2 O75604 1/20 0.67
LMNA P02545 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
PDE10A Q9Y233 1/20 0.62
MAPT P10636 4/20 0.60
GAA P10253 4/20 0.59
ALDH1A1 P00352 4/20 0.59
KMT2A Q03164 3/20 0.59
MEN1 O00255 2/20 0.59
GLA P06280 1/20 0.59
PPARG P37231 1/20 0.59
NCOA2 Q15596 1/20 0.59
NCOA1 Q15788 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
RXFP1 Q9HBX9 1/20 0.59
POLB P06746 2/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31715997 0.98 KDM4E (0.67) KDM4EHTTUSP2LMNASMN1; SMN2
SCHEMBL5781546 0.93 KDM4E (0.61) KDM4EHTTUSP2LMNASMN1; SMN2
SCHEMBL1613027 0.87 KDM4E (0.67) KDM4EHTTUSP2SMN1; SMN2MAPT
SCHEMBL11506441 0.87 KDM4E (0.67) KDM4EHTTUSP2SMN1; SMN2MAPT
SCHEMBL13209738 0.86 KDM4E (0.69) KDM4EHTTUSP2SMN1; SMN2MAPT
SCHEMBL6457986 0.86 KDM4E (0.65) KDM4EHTTUSP2SMN1; SMN2MAPT
SCHEMBL31716523 0.82 ALDH1A1 (0.53) KDM4EHTTUSP2SMN1; SMN2ALDH1A1
SCHEMBL31435202 0.82 HTT (0.71) KDM4EHTTUSP2MAPTGAA
SCHEMBL28535854 0.82 KDM4E (0.64) KDM4EHTTUSP2MAPTGAA
SCHEMBL2537845 0.82 KDM4E (0.64) KDM4EHTTUSP2SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240324255-A1 SOLAR CELL PANASONIC HOLDINGS CORPORATION (JP) 2024-09-26 US claimed
WO-2023106042-A1 SOLAR CELL パナソニックホールディングス株式会社 2023-06-15 WO claimed
CN-112341389-A Nitrogen-containing aromatic heterocycle substituted quinoline formamide derivative and application thereof 浙江工业大学 2021-02-09 CN claimed
US-10401747-B1 Undercoat layer for imaging device XEROX CORPORATION (US) 2019-09-03 US claimed
EP-2379558-B1 NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS MERCK PATENT GMBH (DE) 2016-03-23 EP claimed
US-7981578-B2 Additive containing photoconductors XEROX CORPORATION (US) 2011-07-19 US claimed
US-20090246660-A1 ADDITIVE CONTAINING PHOTOCONDUCTORS XEROX CORPORATION (US) 2009-10-01 US claimed
US-4009020-A QUINOLINE-4-CARBOXYLIC ACID OR SALTS AMCHEM PRODUCTS, INC. (US) 1977-02-22 US claimed
EP-4724430-A1 CONDENSED AZINES AS INHIBITORS OF CYCLIC ADP RIBOSE HYDROLASE Flagship Pioneering Innovations VI, LLC (US) 2026-04-15 EP disclosed
EP-4650002-A1 ANILINE-BASED MODULATORS OF THE NUCLEAR RECEPTOR TLX (NR2E1) Ludwig-Maximilians-Universität (DE) 2025-11-19 EP disclosed
EP-4617270-A1 ISOINDOLINONE DERIVATIVE HAVING QUINOLINE AMIDE STRUCTURE, AND USE THEREOF Oncord Bio Inc (KR) 2025-09-17 EP disclosed
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-07-03 US disclosed
CN-120152966-A Isoindolinone derivative with quinolinamide structure and application thereof 昂科德生物株式会社 2025-06-13 CN disclosed
CN-119585252-A Bicyclic heteroaryl containing compounds as IKZF2 degrading agents 翁科皮亚治疗公司和SK生命科学实验室 2025-03-07 CN disclosed
EP-0714393-A1 THIAZOLES AS ANTIVIRAL PFIZER INC. (US) 1996-06-05 EP disclosed
WO-1995005378-A1 ANTIVIRAL THIAZOLES PFIZER INC. (US) 1995-02-23 WO disclosed
EP-0123146-A2 Compound with antiinflammatory activity, process for preparation thereof and pharmaceutical compositions therefrom CHIESI FARMACEUTICI S.p.A. (IT) 1984-10-31 EP disclosed
US-4123440-A ANTIARRHYTHMIA AND ANTIFIBRILLATORY AGENTS BRISTOL-MYERS COMPANY (US) 1978-10-31 US disclosed
US-4122273-A PROPHYLACTIC, ANTIARRHYTHMIC BRISTOL-MYERS COMPANY (US) 1978-10-24 US disclosed
US-4009020-A QUINOLINE-4-CARBOXYLIC ACID OR SALTS AMCHEM PRODUCTS, INC. (US) 1977-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214991-A1 BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS IKZF1, IKZF2, IKZF3 KDM4E 647/4885HTT 1106/4885USP2 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.